The Centers for Disease Control and Prevention (CDC) has released specific recommendations for dental healthcare professionals to prevent transmission of the 2009 H1N1 Influenza virus.
26/11/2009
NOVABAY Pharmaceuticals has announced preclinical animal data showing that NVC-422, the company's lead Aganocide compound, was effective in treating subcutaneous dermatophyte (skin fungus) infections.
16/03/2009
The US Centers for Disease Control and Prevention (CDC) has released new guidelines for the prevention of catheter-associated urinary tract infections (CAUTI).
09/02/2010
The Federal Government plans to spend approximately AUD$2.6 million over four years to establish RHDAustralia to help combat a potentially fatal heart disease that begins with strep throat. This common bacterial infection mainly affects young Indigenous Australians.
28/01/2010
The Measles Initiative has announced that that measles deaths worldwide fell by 78% between 2000 and 2008, from an estimated 733,000 in 2000 to 164,000 in 2008. However, global immunisation experts warn of a resurgence in measles deaths if vaccination efforts are not sustained.
08/12/2009
US physicians will soon begin implanting a new medical device to improve breathing in patients with upper spinal-cord injuries or conditions that keep them from breathing independently.
30/11/2009
HIV-positive adults are being recruited to participate in a clinical trial of the 2009 H1N1 influenza vaccine. The US study will involve 240 men and women of 18 - 64 years of age.
14/12/2009
RESEARCHERS at the University of Melbourne, Australia have identified a human vaccine against Bird Flu.
16/03/2009
NOVARTIS has been granted Marketing Authorisation by theEuropean Commission for its Ixiaro Vaccine developed for the prevention of Japanese Encephalitis (JE).
06/04/2009
THE FEDERAL Government has launched the National Hand Hygiene Initiative which has been developed to combat healthcare associate infections (HAIs).
08/04/2009
The National Institute of Allergy and Infectious Diseases (NIAID) has released a study suggesting that adults exposed to strains of seasonal H1N1 virus circulating in the population since 1988 may be more able to fight the severity of infection caused by the 2009 H1N1 influenza virus.
18/11/2009
SCHERING-PLOUGH today announced that the US Food and Drug Administration (FDA) has approved new labelling for its PEGINTRON (peginterferon alfa-2b) and REBETOL (ribavirin, USP) combination therapy for treating chronic hepatitis C in patients three years of age and older with compensated liver disease.
16/03/2009
US researchers report that the 2009 H1N1 Influenza virus can damage cells throughout the respiratory airway, as discovered from autopsies of fatal cases. The damage seen is much like that of earlier influenza pandemics in 1918 and 1957.
11/12/2009
PRIORCLAVE will display an unusual exhibit at ACHEMA 09 with stand visitors able to closely examine examples from its range of Laboratory Autoclaves as well as see the autoclaves from a different persective.
28/04/2009
THE CENTRES for Disease Control and Prevention (CDC) has reported additionally confirmed human infections of the Swine Influenza in the United States and internationally.
30/04/2009
The World Health Organization (WHO) and United Nations Children's Fund (UNICEF) have launched an action plan aimed at saving up to 5.3 million children from dying of pneumonia by 2015.
04/11/2009
APPLIED Biosystems has announced the launch of the first integrated real-time PCR solution for measuring residual DNA impurities from Chinese Hamster Ovary (CHO) host cells.
22/05/2009
Menveo, a quadrivalent meningococcal conjugate vaccine from Novartis, has been approved by the US Food and Drug Administration (FDA) for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people 11 to 55 years of age.
01/03/2010
The US Centers for Disease Control and Prevention (CDC) has updated its information regarding how to use the CSL 2009 H1N1 monovalent vaccine. It has also issued guidance on dose spacing and administration with other vaccines.
23/11/2009
The first five Phase III studies by Roche confirm taspoglutide, a human GLP-1 analogue, reduces blood glucose compared with other diabetes treatment options.
16/02/2010